作者投稿
专家审稿
编辑办公
邮件订阅
RSS
Serum IgE Levels in Patients with Bullous Pemphigoid and Its Correlation with the Activity of the Disease
-
摘要:
目的 探讨大疱性类天疱疮(bullous pemphigoid, BP)患者血清中总IgE变化规律以及与BP病情的相关性。 方法 收集北京协和医院皮肤科住院及门诊就诊的有完整临床资料的BP患者59例, 对其血清总IgE在治疗前后的变化规律进行总结, 并对血清总IgE与皮质类固醇激素应用最大剂量、嗜酸性粒细胞总数及间接免疫荧光滴度间的相关性进行分析。 结果 59例BP患者中, 53例(89.83%)血清总IgE升高, 治疗后患者病情好转后IgE下降, 但多不能恢复到正常水平。BP患者总IgE水平与激素应用的最大剂量、嗜酸性粒细胞数量、间接免疫荧光滴度均无相关性(P > 0.05)。 结论 BP患者血清中总IgE水平明显升高, 但BP病情好转后IgE不能恢复正常, IgE水平与BP病情严重程度无关。 Abstract:Objective To investigate serum total IgE level in bullous pemphigoid (BP) patients and its correlation with the activity of disease. Methods A total of 59 BP patients admitted to our department were enrolled in the study. Their clinical data were analyzed. The change of serum total IgE level before and after treatment was observed. The correlations between the total IgE level and the maximum dose of steroid during hospital stay, the number of eosinophils, and indirect immunofluorescence (IIF) titer were analyzed. Results Of these 59 patients, 53 (89.83%) had elevated serum IgE level. After the disease was controlled, IgE decreased but did not return to normal level. High IgE level lasted for several months or years. The serum IgE level in these BP patients was not correlated with the maximum dose of steroid, number of eosinophils, or IIF titer (all P > 0.05). Conclusions Serum IgE remarkably increases in BP patients, and can not return to the normal thresholds even after the disease is controlled. However, it has no correlation with the severity of BP. -
Key words:
- bullous pemphigoid /
- IgE /
- eosinophils /
- steroid /
- indirect immunofluorescence
-
表 1 19例大疱性类天疱疮患者治疗前后总IgE的变化
病例 治疗前(kU/L) 治疗后(kU/L) 1 117 37. 4 2 4633 4789 3 1330 1540 4 2312 4138* 5 655 138 6 ＞5000 3699 7 ＞5000 4423 8 ＞5000 3028 9 4804 1664 10 6. 9 9 11 84. 3 28. 2 12 197 128 13 3902 375 14 970 344 15 150 135 16 26 41. 3 17 ＞5000 3495 18 2911 898 19 712 657 *该患者病情复发时的数据 
下载: 导出CSV
-
[1] Arbesman CE, Wypych JI, Reisman RE, et al. IgE levels in sera of patients with pemphigus or bullous pemphigoid[J]. Arch Dermatol, 1974, 110:378-381. doi: 10.1001/archderm.1974.01630090016003 [2] Asbrink E, Hovmark A. Serum IgE levels in patients with bullous pemphigoid and its correlation to the activity of the disease and anti-basement membrane zone antibodies[J]. Acta Derm Venereol, 1984, 64:243-246. http://www.ncbi.nlm.nih.gov/pubmed/6204487 [3] Ishiura N, Fujimoto M, Watanabe R, et al. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid[J]. J Dermatol Sci, 2008, 49:153-161. doi: 10.1016/j.jdermsci.2007.08.008 [4] Iwata Y, Komura K, Kodera M, et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid[J]. Arch Dermatol, 2008, 144:41-48. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=c9910ad9659c07beff2cbb637e1d675f [5] Tsuji-Abe Y, Akiyama M, Yamanaka Y, et al. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid[J]. J Dermatol Sci, 2005, 37:145-149. doi: 10.1016/j.jdermsci.2004.10.007 [6] Ujiie H, Nishie W, Shimizu H. Pathogenesis of bullous pemphigoid[J]. Dermatol Clin, 2011, 29:439-446. doi: 10.1016/j.det.2011.03.008 [7] Yayli S, Pelivani N, Beltraminelli H, et al. Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid:a useful clue for diagnosis[J]. Br J Dermatol, 2011, 165:1133-1137. doi: 10.1111/j.1365-2133.2011.10481.x [8] Fairley JA, Fu CL, Giudice GJ. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid[J]. J Invest Dermatol, 2005, 125:467-472. doi: 10.1111/j.0022-202X.2005.23853.x [9] Fairley JA, Burnett CT, Fu CL, et al. A pathogenic role for IgE in autoimmunity:bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice[J]. J Invest Dermatol, 2007, 127:2605-2611. doi: 10.1038/sj.jid.5700958 [10] Fairley JA, Baum CL, Brandt DS, et al. Pathogenicity of IgE in autoimmunity:successful treatment of bullous pemphigoid with Omalizumab[J]. J Allergy Clin Immunol, 2009, 123:704-705. doi: 10.1016/j.jaci.2008.11.035 [11] Dimson OG, Giudice GJ, Fu CL, et al. Identification of a potential effector function for IgE autoantibodies in the organspecific autoimmune disease bullous pemphigoid[J]. J Invest Dermatol, 2003, 120:784-788. doi: 10.1046/j.1523-1747.2003.12146.x [12] Messingham KA, Noe MH, Chapman MA. A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid[J]. J Immunol Methods, 2009, 346:18-25. doi: 10.1016/j.jim.2009.04.013 [13] Toosi S, Bystryn JC. Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid[J]. Med Hypotheses, 2010, 74:727-728. doi: 10.1016/j.mehy.2009.10.038 [14] 左亚刚, 刘冰, 李丽, 等.嗜酸性粒细胞水平与大疱性类天疱疮激素应用剂量间的关系[J].中国医学科学院学报, 2012, 34:130-133. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgyxkxyxb201202006 [15] Noe MH, Messingham KA, Brandt DS, et al. Pregnant women have increased incidence of IgE autoantibodies reactive with the skin and placental antigen BP180(type ⅩⅦ collagen)[J]. J Reprod Immunol, 2010, 85:198-204. doi: 10.1016/j.jri.2010.03.005 [16] D'Auria L, Pietravalle M, Mastroianni A, et al. IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid:correlations with eosinophil cationic protein, RANTES, IgE and disease severity[J]. Arch Dermatol Res, 1998, 290:25-27. doi: 10.1007/s004030050272 -
点击查看大图
图(1) / 表(1)
计量
- 文章访问数: 170
- HTML全文浏览量: 48
- PDF下载量: 5
- 被引次数: 0
